NASDAQ: GDRXGoodrx Holdings Inc Stock
$5.40-0.07 (-1.28%)
Updated Sep 26, 2023
GDRX Price
$5.40
Fair Value Price
N/A
Market Cap
$2.15B
52 Week Low
$3.82
52 Week High
$9.37
P/E
270x
P/B
2.4x
P/S
3.05x
PEG
1.11x
Dividend Yield
N/A
Revenue
$745.09M
Earnings
$11.79M
Gross Margin
90.9%
Operating Margin
5%
Profit Margin
1.6%
Debt to Equity
0.89
Operating Cash Flow
$128M
Beta
1.92
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
GDRX Overview
GoodRx Holdings, Inc. operates a telemedicine platform. It alos offers a website/mobile app that tracks prescription drug prices in the U.S. and provides coupons for discounts on medications. Its telemedicine platform, GoodRx Care, allows individuals to consult with a doctor online and obtain a prescription for certain types of medications as well as obtain referrals for medical testing. GoodRx was founded in 2011 and is headquartered in Santa Monica, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GDRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDRX ($5.40) is trading above its intrinsic value of $1.60, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GDRX is poor value based on its earnings relative to its share price (270x), compared to the US market average (14.06x)
P/E vs Market Valuation
GDRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more GDRX due diligence checks available for Premium users.
Be the first to know about important GDRX news, forecast changes, insider trades & much more!
GDRX News
Valuation
GDRX fair value
Fair Value of GDRX stock based on Discounted Cash Flow (DCF)
Price
$5.40
Fair Value
$8.11
Undervalued by
33.38%
GDRX ($5.40) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
270x
Industry
55.14x
Market
14.06x
GDRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GDRX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GDRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.4x
Industry
3.07x
GDRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDRX price to earnings growth (PEG)
For valuing profitable companies with growth potential
GDRX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
GDRX's financial health
Profit margin
Revenue
$189.7M
Net Income
$58.8M
Profit Margin
31%
GDRX's Earnings (EBIT) of $37.24M... subscribe to Premium to read more.
Interest Coverage Financials
GDRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$796.7M
Debt to equity
0.89
GDRX's short-term assets ($919.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDRX's short-term assets ($919.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$29.9M
Investing
-$15.0M
Financing
-$14.0M
GDRX's operating cash flow ($127.77M)... subscribe to Premium to read more.
Debt Coverage Financials
GDRX vs Health Information Service Stocks
Goodrx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.